Summary Dairy foods are postulated to have beneficial effects on blood pressure, body fat, serum lipids, and the incidence of type 2 diabetes. To evaluate the effects of the consumption of milk and dairy products, we performed a randomized dietary intervention trial for 24 wk in Japanese men, aged 20 to 60 y, with 2 or more components of the metabolic syndrome (Clinical trial registration: UMIN000006353). Subjects were randomized to a control group (n598) that received dietary intervention focused on weight control supervised by registered dietitians, and a dairy-consumption group (n5102) that received both dietary intervention and regular home dairy delivery of 400 g/d for 24 wk. Co-primary endpoints included waist circumference, blood pressure, fasting blood sugar (FBS), and serum lipids. The dietary intervention decreased energy intake from 2,150 to 1,850 kcal/d in both groups (p,0.01). Mean rates of compliance with the dairy-consumption intervention were over 90%, resulting in increased calcium intake in the dairy-consumption group from 329 to 667 mg/d (p,0.01). Co-primary endpoints improved in both groups, but the degree of improvement was smaller in the dairy-consumption group (one-sided p50.99). Subgroup analyses specified in the study protocol identified weight and leisure-time physical activity (LTPA) as significant effect modifiers. Differences in changes in systolic blood pressure compared with the control group were 28.0 mmHg (95% CI, 214.0 to 21.9, interaction; p,0.01) in the normal weight group and 25.8 mmHg (211.4 to 20.2, interaction; p50.02) in the moderate-to-high LTPA group, indicating lower systolic blood pressure in the dairy-consumption group among participants in these subgroups. In conclusion, although effects on the co-primary endpoints of dairy consumption were not shown, dairy consumption lowered systolic blood pressure in the subgroups with normal weight and moderate-tohigh LTPA and lowered FBS in the subgroup with normal weight. Key Words dairy consumption, calcium intake, waist circumference, blood pressure, fasting blood sugar nificant effect on body weight (6) , whereas, a systematic review of cohort studies reported that 8 out of 19 cohort studies found protective associations between dairy intake and obesity, weight, or waist circumference (7) . Epidemiologic associations between increased calcium intake and a decrease in the incidence of type 2 diabetes (8) and metabolic syndrome (9) have been suggested but remain controversial. Milk fat is a source of saturated fatty acids, which can adversely affect serum cholesterol levels (10, 11) and insulin sensitivity (12, 13) . On the other hand, several randomized trials showed that an increase in calcium intake was associated with longterm changes in serum cholesterol levels (14, 15) .
The aim of this trial is, therefore, to evaluate the effects of the consumption of milk and dairy products on waist circumference, blood pressure, fasting blood sugar (FBS), and serum lipids in Japanese men with metabolic syndrome.
MATERIALS AND METHODS
Subjects. This was a multicenter, parallel, open, randomized dietary intervention trial undertaken as a part of a regular health examination for employees of a major Japanese company located in Tokyo, Osaka, and Aichi. In October 2010, we recruited 213 men, aged 20 to 60 y, who met two or more of the criteria for metabolic syndrome: body mass index (BMI) of 25 kg/m 2 or more, waist circumference of 85 cm or more, systolic blood pressure (SBP) and diastolic blood pressure (DBP) of 130/85 mmHg or more, FBS of 100 mg/dL or more, total cholesterol of 200 mg/dL or more, and fasting triglycerides of 150 mg/dL or more. Thirteen men withdrew from the study before the start of the intervention (9 in the intervention group and 4 in the control group). A total of 98 men were randomized to the control group and 102 men were randomized to the dairy-consumption group. Subjects treated with antihypertensive or lipid-lowering agents were eligible pending review by an investigator. Current smokers, subjects sensitive or allergic to dairy products, subjects whose clinical laboratory test results indicated the need for treatment as determined by an investigator, subjects who had participated in a clinical trial within 3 mo from the start date of this study, and subjects with a critical disease history, such as cardiac disease, cerebrovascular disease, kidney disease, or diabetes, were excluded from the study. Details about the recruitment, randomization, and follow-up of this trial appear in Fig. 1 . Written informed consent was obtained from all participants. The study protocol was approved by the ethics committees of Kagawa Nutrition University and HuBit Genomix, Inc. This study is registered as UMIN000006353.
Intervention. This study was reviewed and approved by the internal review board and conducted in compliance with the Declaration of Helsinki and local regulations. Subjects were randomly assigned with a 1 : 1 ratio either to a dairy-consumption group that received home delivery of dairy products or a control group. Random assignment was stratified by age, BMI, and office location. The allocation sequence was determined by the contract research organization using computergenerated random numbers that were concealed from the investigators and subjects. Owing to the nature of the intervention, the trial was not blinded.
The dairy-consumption group received regular home delivery of milk and dairy products (400 g/d) free of charge for 24 wk. Subjects in both the control and dairy consumption groups received dietary counseling focused on weight control from registered dietitians. Preferable energy intake of each subject was set by calculating the reference body weight multiplied by 25 to 30 kcal/kg/d, including energy from milk and dairy products for those in the dairy-consumption group. These subjects were given a choice to take either 400 g/d of milk, or a combination of milk plus yogurt.
Before the intervention, a dietitian provided a 90-min nutritional guidance session for each group. Before the study, subjects compiled a 3-d dietary record (2 weekdays and 1 weekend) that registered dietitians used to assess subjects' previous dietary habits. During the study, all subjects uploaded a 2-d dietary record (including 1 weekday and 1 weekend day) to an assigned dietitian, who offered dietary advice to help ensure compliance. Subjects compiled the 2-d dietary record weekly for the first 2 wk and then biweekly for the 3rd week to the 24th week. Measurements and data collection. Dietary and lifestyle assessments as well as clinical and laboratory tests were performed at baseline, 12 wk, and 24 wk. Dietary intake was assessed or calculated using a semiquantitative questionnaire, the Food Frequency Questionnaire for the Prevention and Management of Osteoporosis, a 28-item questionnaire that measures nutritional intake relevant to bone health in adult Japanese women (16) , with coefficients determined by the Standard Tables of Food Composition in Japan (17) . Leisure-time physical activity (LTPA) was assessed using a self-administered questionnaire, nearly identical to that used and validated in the Health Professionals' Follow-up Study (18) . Results were expressed in metabolic equivalents (METs), based on the newest compendium of Ainsworth et al. (19) . Minutes spent on all activities multiplied by the coefficients were added to yield a MET-hour score per week. One MET, the energy expended by sitting quietly, is equivalent to 3.5 mL of oxygen uptake per kilogram of body weight per minute. The frequency of milk and dairy intake and the occurrence of adverse events during the intervention were recorded based on input from each subject's diary.
Waist circumference was measured by registered nurses on the periumbilical area with the subject standing. Blood pressure was measured using an Omron Blood Pressure Monitor (Omron Healthcare, Osaka, Japan) twice at each visit with a 5-min rest before the second measurement. FBS, HbA1c, serum high-density lipoprotein (HDL)-and low-density lipoprotein (LDL)-cholesterol and fasting triglycerides were measured at a central laboratory (Mitsubishi Chemical Medience Corporation, Tokyo, Japan). A body composition monitor (BC-306, Tanita Corporation, Tokyo, Japan) was used to measure the percentage of subjects' body fat.
Statistical considerations. Co-primary endpoints were changes in waist circumference, SBP and DBP, FBS, serum HDL-cholesterol and fasting triglyceride concentrations after 24 wk. Secondary endpoints were body weight, body fat percentage, HbA1c, and serum LDLcholesterol and total cholesterol concentrations after 24 wk. Self-reported compliance rates in the dairy-consumption group were calculated as the days when subjects took milk and dairy products divided by the days when subjects were given milk and dairy products, based on subjects' diaries. A sample size of 100 subjects per group was used to provide 70% power to detect a minimum clinically meaningful effect on SBP (2.5 mmHg; p50.05), as demonstrated in previous studies (6, 20) .
To adjust for multiplicity, we compared the weighted average of co-primary endpoints using the O'Brien one-sided test (21) . Effect modifications by obesity (BMI$25 kg/m 2 ), hypertension (SBP$140 mmHg, DBP$90 mmHg, or treatment by blood-lowering agents), type 2 diabetes (FBS$126 mg/dL, HbA1c$ 6.5%, or treatment by insulin or oral hypoglycemic agents), dyslipidemia (LDL-cholesterol$140 mg/dL, HDL-cholesterol#40 mg/dL, fasting triglycerides$150 mg/dL, or treatment by lipid-lowering agents), compliance rate ($90%), excess energy intake ($2,650 kcal/d), calcium insufficiency (,650 mg/d) and low LTPA (#3 MET h/wk) were examined by interaction tests using linear models. Among the eight stratification factors, results for type 2 diabetes, low compliance rates, and sufficient calcium intake were not shown because of the low number of subjects in these subgroups. All analyses were performed according to the intention-totreat principle and included all randomized patients in the groups to which they were assigned. All statistical analyses were performed by an academic biostatistician (S.T.) using SAS software version 9.2 (SAS Institute Inc, Cary, NC). Role of the funding source. The Japan Dairy Association provided financial support for this study. Y.T., Executive Director of the funding source and one of the authors who conceived the idea for the study, participated in the design and substantive editing of the manuscript. All authors had full access to the data and jointly made the decision to publish the manuscript.
RESULTS
A total of 213 men were randomized; however, 9 men in the control group and 4 in the dairy-consumption group withdrew before starting the intervention. Consequently, they are not included in the intention-to-treat analysis. Baseline characteristics and lifestyle factors were balanced between groups (Table 1 and Table 2 ). The mean age of subjects was 41.7 y. More than half of subjects were obese, but the prevalence of hypertension, type 2 diabetes, and dyslipidemia was low. Mean energy and calcium intake at baseline were approximately 2,150 kcal/d and 300 mg/d, respectively, and fat intake was approximately 25% of the total energy intake.
A total of 98 subjects (100%) in the control group and 101 of the 102 subjects (99%) in the dairy-consumption group were observed for 24 wk (Fig. 1) . Mean rates of compliance with the intervention, i.e., the percent of days that subjects consumed the requisite amount of milk and dairy products in the first and second 12 wk, were 94.2% and 92.7%, respectively. Thirteen subjects (13%) in the dairy-consumption group developed mild gastrointestinal symptoms, such as vomiting, diarrhea, and abdominal pain, but all recovered within 9 d. After the 24-wk dietary intervention, the mean energy intake decreased from 2,150 kcal/d (baseline level) to 1,850 kcal/d in both groups (p,0.01). LTPA also decreased by more than two MET h/wk in both groups ( Table 2 ). The intake of milk and yogurt increased by 266.8 g/d and 47.6 g/d, respectively, in the dairy-consumption group (p,0.01). In the control group, on the other hand, milk and yogurt consumption over 24 wk did not differ from baseline. There were no significant differences in other foodstuffs or proportions of protein, fat, and carbohydrate between the groups (Table 2) . Therefore, the intervention mainly led to an increase in calcium intake (329 mg/d to 667 mg/d, p,0.01). The intakes of total energy and salt at 24 wk were not significantly different between the control and dairy-consumption groups when subjects were stratified by body weight and LTPA (Table 3) . After 24 wk, waist circumference, blood pressure, FBS, body weight, body fat percentage, HbA1c, LDLcholesterol, and total cholesterol decreased significantly in both groups (Table 4) . HDL-cholesterol also increased in the control group, but remained unchanged in the dairy-consumption group. The degree of improvement in waist circumference, HDL-cholesterol, weight, body fat percentage, HbA1c, and LDL-cholesterol was significantly smaller in the dairy-consumption group than in the control group. The efficacy of dairy consumption, therefore, was not shown in the primary analysis (p50.99, the one-sided O'Brien test). Table 5 shows the results of a subgroup analysis using the pre-specified stratification factors, obesity, hypertension, dyslipidemia, excess energy intake, and low LTPA. Only body weight and LTPA were identified as effect modifiers with significance in interaction tests. The difference in changes in waist circumference between the two groups was near null in subjects with normal weight (difference: 20.8 cm [95% confidence interval: 23.1 to 1.6]), while increases in waist circumference in the obesity subgroup were substantially greater (difference: 2.7 cm [1.3 to 4.0]). The dietary-intervention interaction focused on decreased energy intake was significant (p50.01). Qualitatively similar trends were observed for LTPA; the effect on waist circumference was 0.0 cm (21.8 to 1.8) for subjects with moderateto-high LTPA. For subjects with low LTPA (interaction; p50.02), the effect on waist circumference was 2.8 cm (1.3 to 4.3) . Notably, dairy consumption lowered SBP in both subgroups and FBP in the normal-weight subgroup. Differences in SBP were 28.0 mmHg (214.0 to 21.9, interaction; p,0.01) for subjects with normal weight, 1.2 mmHg (22.3 to 4.7) for obese subjects, 25.8 mmHg (211.4 to 20.2, interaction; p50.02) for subjects with moderate-to-high LTPA, and 2.0 mmHg (21.6 to 5.5) for subjects with low LTPA. Differences in FBS were 22.2 mg/dL (25.6 to 1.2, interaction; p50.04) for subjects with normal weight and 2.0 mg/ dL (20.0 to 4.0) for obese patients, but differences in FBS in the various levels of LTPA were not significantly different. Interaction tests for HDL-cholesterol did not show any significant differences.
DISCUSSION
To our knowledge, no published randomized intervention trial has examined the effects of milk and dairy products in an Asian population. In Western countries, the effects of milk and dairy products on weight reduction were investigated in several intervention trials, reporting both positive (22, 23) and negative effects (6, (24) (25) (26) . Subjects in these studies were obese, i.e., having a mean BMI of 30 kg/m 2 or more (6, (22) (23) (24) (25) , with the exception of one trial with normal-weight young women (26) . Our study population had relatively low initial calcium intake and included few subjects with a BMI of more than 30 kg/m 2 (n529). Subjects in the control group consumed less energy than the estimated energy requirement in Japan, and their fat intake was within the range of the tentative dietary goal for preventing lifestyle-related diseases (27) . Although calcium intake in the dairy-consumption group increased significantly, changes in waist circumference, body weight and body fat in the dairy-consumption group were significantly smaller than those in the control group. These findings are not consistent with earlier studies, which observed the effects of calcium on weight loss (22, 23) . The two positive trials previously published are relatively short (12-and 24-wk intervention), but the calcium and energy intake during these interventions were approximately 1,100 mg/d and 1,400 kcal/d (22, 23) . Thus, findings inconsistent with our study may be attributable to the type of intervention, as well as subjects' body weight and ethnic factors.
SBP in the dairy-consumption group was lower than that in the control group by 1.0 mmHg. Furthermore, the difference in SBP was 8.0 mmHg in the subgroup with normal weight, and 5.8 mmHg in the subgroup with moderate-to-high LTPA, although intakes of total energy and salt were not different between the dairyconsumption and control groups at baseline and 24 wk. Meta-analyses of randomized trials have reported a 22.6 mmHg reduction in SBP with calcium supplementation (3) and a 24.8 mmHg reduction in SBP with milk tripeptides (4) in populations with relatively low calcium intake. Calcium deficiency can increase the parathyroid hormone level, which in turn increases blood pressure (28) . Other mechanisms that potentially explain our findings include direct effects on vascular smooth muscle, calcium regulation, and calciumsensitive hormones; interactions between calcium and sodium potassium; and an increased appetite for sodium when calcium intake is low (28) . In addition to calciumrelated mechanisms, milk-derived tripeptides are potent inhibitors of angiotensin-converting enzymes (4). The results of meta-analyses (4, 5) , therefore, support the hypotensive effects of milk and dairy products observed in this study. We found that the hypotensive effects of dairy-consumption were greater in the subgroups with normal weight and moderate-to-high LTPA. Because nutrients other than calcium intake did not result in significant differences between groups at 24 wk, the differences in SBP between groups in these subgroups may be mainly attributable to calcium. Data supporting these findings are limited since most of the previously published intervention trials did not report subgroup analyses, presumably because of their small sample size. The ENCORE study, however, recently showed that weight loss and aerobic exercise combined with the Dietary Approaches to Stop Hypertension (DASH) diet-a diet high in low-fat dairy products, fruits, and vegetables; lower in saturated fat, total fat, and cholesterol; and rich in fiber-further lowered blood pressure (29) . Thus, the ENCORE study suggested beneficial synergistic effects of dietary factors (including dairy products), weight control, and exercise. This corroborates the observations in our study. The combination of milk and dairy products plus exercise is worthy of further research, although the mechanism of the synergism is unknown. We also found an effect of dairy consumption on FBS by 22.2 mg/dL in normal-weight subjects. This observation is inconsistent with the randomized trial of dairy products in Nordic Countries (6) , which showed no significant differences in FBS or HbA1c between the milk consumption group and the control group. Explanations for the discrepancies between these 2 trials are not readily apparent, but may be related to differences in body weight, since the trial in Nordic countries included subjects of mean BMI around 30 kg/m 2 . In epidemiologic studies, vitamin D and calcium insufficiency can negatively influence glycemia (8) . In the Women's Health Study, higher intakes of dairy products were associated with a decreased risk of type 2 diabetes in middle-aged or older women. The risk ratios were smaller in a subset of women with a BMI lower than 25 kg/m 2 (30) . Therefore, the effect of dairy consumption on FBS we observed is supported by epidemiologic studies, but not by clinical trials. The mechanisms for the lack of effect on FBS in obese subjects are unclear; however, dysregulation of glucose metabolism, which can be triggered by obesity, may play a role. An obesity-associated increase in fatty acids can activate serine/threonine kinases that inhibit insulin signaling.
In conclusion, although effects on the co-primary endpoints of dairy consumption were not shown, dairy consumption lowered SBP in the subgroups with normal weight and moderate-to-high LTPA and lowered FBS in the subgroup with normal weight.
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